HC Wainwright Has Pessimistic View of AnaptysBio Q2 Earnings

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for AnaptysBio in a research report issued to clients and investors on Tuesday, May 6th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn ($1.81) per share for the quarter, down from their prior forecast of ($1.58). HC Wainwright currently has a "Neutral" rating and a $22.00 price target on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio's Q3 2025 earnings at ($1.86) EPS, Q4 2025 earnings at ($2.11) EPS, FY2025 earnings at ($7.02) EPS, FY2026 earnings at ($6.82) EPS, FY2027 earnings at ($9.96) EPS, FY2028 earnings at ($8.90) EPS and FY2029 earnings at ($6.81) EPS.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $27.77 million for the quarter, compared to analyst estimates of $15.27 million.

Several other brokerages have also recently weighed in on ANAB. Johnson Rice reaffirmed a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Wells Fargo & Company increased their price target on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Wedbush reissued an "outperform" rating and set a $40.00 price objective on shares of AnaptysBio in a research note on Thursday, May 1st. Wolfe Research initiated coverage on shares of AnaptysBio in a report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 target price for the company. Finally, Guggenheim boosted their price target on AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $35.88.

AnaptysBio Trading Up 0.1 %

AnaptysBio stock traded up $0.01 during trading hours on Thursday, hitting $19.59. 421,018 shares of the stock traded hands, compared to its average volume of 597,975. AnaptysBio has a one year low of $12.21 and a one year high of $41.31. The firm's 50-day moving average price is $18.63 and its two-hundred day moving average price is $18.59. The company has a market cap of $579.35 million, a PE ratio of -3.22 and a beta of -0.20.

Institutional Trading of AnaptysBio

A number of large investors have recently made changes to their positions in ANAB. BIT Capital GmbH bought a new stake in AnaptysBio in the 1st quarter worth approximately $473,000. DCF Advisers LLC purchased a new stake in AnaptysBio in the first quarter worth about $648,000. US Bancorp DE boosted its position in shares of AnaptysBio by 126.5% in the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 979 shares during the period. Corton Capital Inc. purchased a new stake in AnaptysBio in the 1st quarter worth $199,000. Finally, Skandinaviska Enskilda Banken AB publ purchased a new position in AnaptysBio in the 1st quarter worth approximately $623,000.

AnaptysBio declared that its Board of Directors has authorized a share buyback plan on Monday, March 24th that permits the company to buyback $75.00 million in shares. This buyback authorization permits the biotechnology company to reacquire up to 13.1% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.